Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus PEDIAMYCIN 400.
E.E.S. 200 vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic